  |
|
PAD is a serious, chronic condition that affects more than 200 million people worldwide.1 In PAD, arteries in the legs become narrowed or blocked by plaque. This narrowing of the blood vessel reduces blood flow to the leg, which can result in severe pain and limit physical mobility. Blocked arteries below the knee are more likely to be calcified, linked to lower treatment success,2 and may also develop into critical limb ischemia (CLI), which can result in non-healing leg ulcers and increased risk of amputation.3, 4 "Directional atherectomy is an established treatment modality for patients with complex PAD to restore patency, maximize luminal gain and preserve future treatment options," said Professor Thomas Zeller, M.D., head, Department of Angiology at Universitäts-Herzzentrum Freiburg, Bad Krozingen, Germany. "The new smaller HawkOne 6F size is an advanced option to treat patients with multi-level PAD, addressing lesions of various length, morphology, and location, particularly those below the knee." The HawkOne system also enables physicians to treat severe calcified lesions more efficiently with no increase in cut depth. The system can treat calcified lesions up to two times more effectively than the TurboHawk™ device.5 The HawkOne system has a preloaded flush tool, which improves cleaning time by up to 55 percent when compared to the TurboHawk high efficiency cutter.6 The 6F size is designed to simplify device selection and provide easy set-up with no capital equipment. "We are excited to announce CE Mark approval for HawkOne 6F shortly after receiving FDA clearance for the system in October," said Mark Pacyna, vice president and general manager of the Peripheral business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "The HawkOne 6F system provides physicians with an effective and efficient treatment option for treating PAD above and below the knee and reinforces our commitment to expand access to therapy innovations that protect limbs and enhance lives." In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world. About Directional Atherectomy
Results from DEFINITIVE LE demonstrated 95 percent limb salvage in patients with critical limb ischemia (CLI) and 78 percent overall patency in claudicant patients 12 months post treatment.8 A subset analysis of DEFINITIVE LE in claudicant patients with infrapopliteal disease observed 12-month patency rates of approximately 90 percent.9 Both DEFINITIVE LE and DEFINITIVE AR showed low dissection and provisional stent rates when patients were treated with directional atherectomy.9 Furthermore, directional atherectomy can also be used as an adjunctive treatment prior to using the Medtronic IN.PACT® Admiral® drug-coated balloon. About Medtronic
|
